Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer - Wikidata - awgldk - TriplyDB

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer

http://www.wikidata.org/entity/Q35951620

about

Genomic alterations in pancreatic cancer and their relevance to therapy Improving the efficacy of chemoradiation with targeted agents ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.Kras as a key oncogene and therapeutic target in pancreatic cancer Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K)Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.Molecular-targeted agents combination therapy for cancer: developments and potentials.Mitogen-activated protein kinases and their role in radiation response.Radiation oncology in vitro: trends to improve radiotherapy through molecular targets.Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.Biological determinants of radioresistance and their remediation in pancreatic cancer.Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer.

P2860

Q26781443-C81B1545-238D-4AF1-80EF-61F0551F2FC1 Q26850193-D83C9994-AC68-452E-B56A-5C606FC2794D Q34295427-C803BD4C-59AD-47CC-83A9-E8B5B9EF18C6 Q34659332-CEB88436-8517-4B59-A625-8E4275342024 Q35018805-15FC126F-C37A-40B6-9547-2684050ED39E Q35161368-1D5E9265-1878-4AC4-A1EE-C0BCCE1A65C5 Q35207897-07884242-4EA7-46D8-BF72-2D815A7B23E1 Q35727558-1490D38A-D063-4BF3-B39A-FCC63E4415C7 Q35728606-2C9BE774-CCD7-4A0B-9E37-AD4462695919 Q36010627-3387A4AA-5043-4A56-9C75-E224353632FE Q36613302-7615DA7F-A94A-4EE8-97E1-2BD3609C627B Q36781119-BA0F9E56-599F-4C8D-8776-1AD62C9C9B50 Q36826875-4DB73CA3-7DB7-48AF-9817-4088989650B3 Q37254508-2AFA7F9A-ADAB-4172-9472-D4ABB1D28319 Q37403232-28BD4573-6E02-4540-A5B5-FC87FC082DEA Q37520294-EFF4FC1D-9D31-449E-8230-8D1D53EF0068 Q37536691-BAD7B9DB-DFC9-4925-9C82-8A296B90DE29 Q38104670-31BA38E5-033B-428D-AFAB-EA409E8E8EC7 Q38172165-DB084AFB-09B4-4A89-8A4B-620510B75071 Q38258770-6E7EB166-304B-4477-AF7C-06701BC15A7D Q38825141-B375B0DE-4623-4A0E-8B4A-94CCF98DE3CC Q39013961-9D13EAD8-D1D9-47A3-B216-32FB69C01D60 Q39156722-C61DDDB8-46A2-4043-9384-023B32B45C1E Q42242957-6798914E-C63A-4702-8A24-4B9B049EDFAA Q47123455-9A2BEFFE-0750-4B70-9981-A3EAA8334081 Q47760790-2AB5A6F2-7309-416C-B021-B1E18BAC5513 Q47782363-5CB81A4D-7A1C-409C-A566-025CB5E91FBB Q53795429-02BE58BE-497A-48A2-A3D7-0D145A225803

P2860

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer

http://www.wikidata.org/entity/Q35951620

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@ast

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@en

type

label

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@ast

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@en

prefLabel

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@ast

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@en

P1433

Q35951620-CA175B15-0962-4888-9C21-2F9F27714846

P1476

Q35951620-2EF13FEA-599B-4E52-A779-41EBF5620C87

P2093

Q35951620-11D51D79-038F-4E2B-84E8-39D2C7281DAB

Q35951620-1A2CE7FA-AAC1-479B-84D0-5B31814BB08C

Q35951620-50A681A3-5E81-487E-822B-132EF297C365

Q35951620-593B1594-CB40-4EB9-8096-27031BCB75EB

Q35951620-6766F4FC-F6A3-4A07-A50C-D8812DD51161

Q35951620-72F5C664-0366-4A5D-B589-0372273D2D5C

Q35951620-8EE86AF2-5B97-42A2-BD06-AFBF1CB83846

Q35951620-959CB7C7-FF58-4E8E-B23E-6007542044FB

Q35951620-9FE02869-BAD2-479A-849D-BA4C17A2342C

Q35951620-D267851C-A1CA-44E7-9165-00AE987DBA9D

P2860

Q35951620-02233C79-D32B-4F7E-B6C7-41FDF858875D

Q35951620-03CEA11A-D5D7-45B5-B579-96AA7B2ED599

Q35951620-06A2D67F-ECFB-45C2-9188-40223CE22C57

Q35951620-07487CA3-0415-46A8-9158-8EDEBB8432AA

Q35951620-08B26303-FDCE-4794-B58C-F142A50FFEE7

Q35951620-0A7A5116-85CC-4093-AB21-786B8138E371

Q35951620-0E4309F0-5E6E-4086-867E-296A709CAFAB

Q35951620-2C92266C-2F6B-4CC1-9C7F-5EA42378C26B

Q35951620-3330D81C-1E1E-4361-98C7-B9257C19331B

Q35951620-386F0E0D-7773-4159-B8D5-D7B28366A932

P304

Q35951620-851E7927-F467-4758-8C59-52C8F097F01B

P31

Q35951620-F98A11E1-611A-46AF-8954-CE81BFD0F893

P356

Q35951620-C4B7027A-C62B-43C8-9F6B-CFC3CC29F824

P433

Q35951620-00E31795-B501-4851-AE19-AB0AB43279B1

P478

Q35951620-6179F85F-EB2D-476D-8802-8A07B4788D72

P50

Q35951620-209EBEE9-AAEB-4BC7-B32D-2D037B110629

P577

Q35951620-BB523E50-2CFE-4A67-9BEF-286887E50184

P698

Q35951620-93D19605-1E9E-49AA-8279-EA95370B7B3D

P921

Q35951620-856C39FA-4799-42B4-B277-2FB526BABFA4

P932

Q35951620-AC0327DE-C601-441F-8331-0C92671D26A7

P356

1535-7163.MCT-12-0098

P1433

Molecular Cancer Therapeutics

P1476

Cotargeting MAPK and PI3K sign ...... treatment of pancreatic cancer

@en

P2093

Alnawaz Rehemtulla

http://www.w3.org/2001/XMLSchema#string

Athena R Flecha

http://www.w3.org/2001/XMLSchema#string

Brian D Ross

http://www.w3.org/2001/XMLSchema#string

Craig J Galbán

http://www.w3.org/2001/XMLSchema#string

David Karnak

http://www.w3.org/2001/XMLSchema#string

Judith Sebolt-Leopold

http://www.w3.org/2001/XMLSchema#string

Paul Keller

http://www.w3.org/2001/XMLSchema#string

Stefanie Galbán

http://www.w3.org/2001/XMLSchema#string

Terence M Williams

http://www.w3.org/2001/XMLSchema#string

Theodore S Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

BRAF mutation predicts sensitivity to MEK inhibition

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

P304

1193-1202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-12-0098

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22411900

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3349776

http://www.w3.org/2001/XMLSchema#string